Showing posts from July, 2008

Should parents be concerned about baby bottles?

Glass bottles and containers have been more or less been completely supplanted by plastic bottles and containers. However, lately there have been growing concerns that the plastic bottles and containers may be contributing to earlier maturation of our young ones. When my wife learned that plastics may be involved in causing girls to attain premature puberty, the plastic containers in our house were quickly replaced with glass containers.

Today I read that Walmart is pulling plastic baby bottles containing BPA off the shelf because they are implicated in causing many problems including chromosomal abnormalities, developmental disabilities, mental retardation etc.

Photo: Egg on Stilts

Parents tend to be most cautious about their little ones, so I expect parents to start looking feverishly to replace the plastic bottles with something that doesn't contain BPA. Companies like Gerber and Avent are capitalizing on this by introducing BPA free plastic bottles. But how about the good…

Challenges of Developing and Commercializing New Pharmaceutical Drugs

The pharmaceutical industry is grappeling with a very serious problem - how to get the payers to pay for the drugs they develop. Increasingly, governments and other healthcare payers are refusing to pay for new drugs that took years to develop but add relatively "small" real value to the patients. An example of this is the recent rejection by NICE (the UK body that advices the Government on whether or not to reimburse a medicine) of Tyverb, a GSK developed HER2 inhibitor, on the basis that the drug did not meet their threshold of cost and effectiveness.

GSK is clearly concerned about this. In an interview to the Wall Street Journal Andrew Witty, the Chief Executive of GlaxoSmithKline PLC said that GSK recently invited a group of health care officials from UK, France, Italy and Spain to comment on the drugs being developed in the GSK labs. While it is not uncommon for pharmaceutical companies to interact with regulatory authorities about a particular drug, it is quite unu…

Nikon D700

Photographers world wide have something new to drool on!

A full frame camera at half the price of D3